GLP1R and type 2 diabetes mellitus: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and the dual incretin receptor agonist tirzepatide have a major, and increasing, impact on the current management of type 2 diabetes (T2D) and obesity.